DE69910559D1 - Neue fettanaloge zur behandlung der fettleibigkeit - Google Patents

Neue fettanaloge zur behandlung der fettleibigkeit

Info

Publication number
DE69910559D1
DE69910559D1 DE69910559T DE69910559T DE69910559D1 DE 69910559 D1 DE69910559 D1 DE 69910559D1 DE 69910559 T DE69910559 T DE 69910559T DE 69910559 T DE69910559 T DE 69910559T DE 69910559 D1 DE69910559 D1 DE 69910559D1
Authority
DE
Germany
Prior art keywords
sub
treatment
obesity
new fat
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69910559T
Other languages
English (en)
Other versions
DE69910559T2 (de
Inventor
Rolf Berge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thia Medica AS
Original Assignee
Thia Medica AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica AS filed Critical Thia Medica AS
Publication of DE69910559D1 publication Critical patent/DE69910559D1/de
Application granted granted Critical
Publication of DE69910559T2 publication Critical patent/DE69910559T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69910559T 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit Expired - Lifetime DE69910559T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
WOPCT/NO98/00143 1998-05-08
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (2)

Publication Number Publication Date
DE69910559D1 true DE69910559D1 (de) 2003-09-25
DE69910559T2 DE69910559T2 (de) 2004-06-17

Family

ID=19907879

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69909775T Expired - Lifetime DE69909775T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes
DE69910559T Expired - Lifetime DE69910559T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung der fettleibigkeit
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DE69932864T Expired - Lifetime DE69932864D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung des Bluthochdrucks
DE69932645T Expired - Lifetime DE69932645D1 (de) 1998-05-08 1999-04-23 Neue Fettsäureanaloge zur Behandlung der Fettleber
DE69909775T Expired - Lifetime DE69909775T2 (de) 1998-05-08 1999-04-23 Neue fettanaloge zur behandlung von diabetes

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69927805T Expired - Fee Related DE69927805T2 (de) 1998-05-08 1999-05-07 Neue fettanaloge zur behandlung von sekundärer restenose

Country Status (18)

Country Link
US (4) US6441036B1 (de)
EP (5) EP1075259B1 (de)
JP (3) JP5057003B2 (de)
KR (3) KR100701503B1 (de)
CN (3) CN1223343C (de)
AT (5) ATE336239T1 (de)
AU (4) AU7240398A (de)
BR (2) BR9910297A (de)
CA (3) CA2331395C (de)
DE (5) DE69932864D1 (de)
DK (3) DK1075258T3 (de)
ES (3) ES2207253T3 (de)
HK (3) HK1034909A1 (de)
NO (3) NO20005461L (de)
NZ (3) NZ508047A (de)
PT (2) PT1075259E (de)
RU (3) RU2219920C2 (de)
WO (4) WO1999058120A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
ATE495740T1 (de) * 2002-05-28 2011-02-15 Ajinomoto Kk Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
EP1515978A1 (de) 2002-06-20 2005-03-23 IC Vec Limited Schwefelhaltige phospholipidderivate
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
KR20050033662A (ko) 2002-09-06 2005-04-12 얀센 파마슈티카 엔.브이. 헤테로사이클릭 화합물
CA2499983A1 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Docohexaenoic acid for improved glycemic control
MXPA05003870A (es) * 2002-10-10 2005-06-22 Yeda Res & Dev Esteres basicos de alcoholes grasos y su uso comun como agentes antiflamatorios o inmunomoduladores.
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
WO2004071458A2 (en) * 2003-02-13 2004-08-26 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
JP2007522118A (ja) * 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
WO2005119250A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
KR20070054637A (ko) * 2004-07-19 2007-05-29 티아 메디카 에이에스 식물유 및/또는 어유 및 비-산화성 지방산 구성요소를포함하는 조성물
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
US20090203778A1 (en) * 2005-05-04 2009-08-13 Morten Bryhn Fatty acid analogues, i.e. including dha derivatives for uses as a medicament
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
WO2008051902A2 (en) * 2006-10-20 2008-05-02 Cpd, Llc Method of restoring the incretin effect
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
US20100240616A1 (en) * 2006-11-01 2010-09-23 Anne Kristin Holmeide Novel lipid compounds
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2009052182A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
US20100267828A1 (en) * 2007-10-31 2010-10-21 Anne Kristin Holmeide dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
JP5373888B2 (ja) * 2008-04-29 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｐｔ２インヒビターとしての４−トリメチルアンモニオ−ブチラート類
EP2147910A1 (de) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
MY165292A (en) 2009-05-08 2018-03-21 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2769030C (en) 2009-07-30 2016-05-10 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
WO2012059818A1 (en) 2010-11-05 2012-05-10 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP2961384B1 (de) 2013-02-28 2019-08-28 Basf As Zusammensetzung mit einer lipidverbindung, einem triglycerid und einem tensid sowie verfahren zur verwendung davon
US10154979B2 (en) 2013-03-11 2018-12-18 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
AU2014229506B2 (en) 2013-03-11 2017-04-13 Nobesita As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
CN107405343A (zh) 2014-11-07 2017-11-28 明尼苏达大学董事会 可用于治疗疾病的盐和组合物
BR112017023164A2 (pt) 2015-04-28 2018-07-24 Pronova Biopharma Norge As composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
KR20200075815A (ko) * 2017-10-23 2020-06-26 에피트래커, 인코포레이티드 지방산 유사체 및 대사 증후군 관련 병태 치료에서의 그의 용도
IL275002B2 (en) 2017-12-06 2024-04-01 Basf As Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
EP3934639A4 (de) * 2019-03-04 2023-01-11 Epitracker, Inc. Fettsäureanaloge und deren verwendung zur behandlung von kognitiven beeinträchtigungen, verhaltenszuständen und chronischen schmerzen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
ATE377418T1 (de) * 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 Nutricia Nv Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Also Published As

Publication number Publication date
CN1302204A (zh) 2001-07-04
RU2221558C2 (ru) 2004-01-20
WO1999058121A1 (en) 1999-11-18
NZ508045A (en) 2003-08-29
AU7240398A (en) 1999-11-29
NO20005461D0 (no) 2000-10-30
WO1999058122A1 (en) 1999-11-18
NO20005462D0 (no) 2000-10-30
KR20010043314A (ko) 2001-05-25
DE69909775T2 (de) 2004-06-03
CN1300212A (zh) 2001-06-20
EP1075258B1 (de) 2003-08-20
CA2331393A1 (en) 1999-11-18
ATE336239T1 (de) 2006-09-15
ES2204142T3 (es) 2004-04-16
US7026356B2 (en) 2006-04-11
DE69927805D1 (de) 2006-03-02
EP1284139B1 (de) 2006-08-02
ATE306916T1 (de) 2005-11-15
ATE334666T1 (de) 2006-08-15
DE69932864D1 (de) 2006-09-28
US6417232B1 (en) 2002-07-09
CA2331408A1 (en) 1999-11-18
EP1075259A1 (de) 2001-02-14
EP1075259B1 (de) 2003-07-23
DK1075259T3 (da) 2003-11-03
CA2331393C (en) 2009-08-11
AU762790B2 (en) 2003-07-03
HK1034911A1 (en) 2001-11-09
DE69927805T2 (de) 2006-07-06
ATE245416T1 (de) 2003-08-15
EP1075260A2 (de) 2001-02-14
DE69909775D1 (de) 2003-08-28
CN1223343C (zh) 2005-10-19
JP5057003B2 (ja) 2012-10-24
NZ508046A (en) 2003-08-29
KR20010043315A (ko) 2001-05-25
CN1300211A (zh) 2001-06-20
NO333143B1 (no) 2013-03-18
AU761355B2 (en) 2003-06-05
ES2207253T3 (es) 2004-05-16
AU4936699A (en) 1999-11-29
EP1075260B1 (de) 2005-10-19
HK1034912A1 (en) 2001-11-09
BR9910296A (pt) 2002-01-15
CN1245157C (zh) 2006-03-15
US6441036B1 (en) 2002-08-27
NO20005463L (no) 2001-01-08
EP1075258A1 (de) 2001-02-14
WO1999058123A2 (en) 1999-11-18
NZ508047A (en) 2003-05-30
CA2331395A1 (en) 1999-11-18
RU2223095C2 (ru) 2004-02-10
PT1075259E (pt) 2003-12-31
JP4465672B2 (ja) 2010-05-19
AU5451799A (en) 1999-11-29
JP2002514594A (ja) 2002-05-21
RU2219920C2 (ru) 2003-12-27
US20020198259A1 (en) 2002-12-26
JP2002514596A (ja) 2002-05-21
KR20010043316A (ko) 2001-05-25
CN1244323C (zh) 2006-03-08
NO20005463D0 (no) 2000-10-30
EP1285652A1 (de) 2003-02-26
PT1075258E (pt) 2004-01-30
KR100701502B1 (ko) 2007-04-02
CA2331395C (en) 2008-10-14
DE69910559T2 (de) 2004-06-17
NO20005461L (no) 2001-01-08
HK1034909A1 (en) 2001-11-09
KR100701503B1 (ko) 2007-04-02
WO1999058123A3 (en) 2000-03-09
BR9910297A (pt) 2002-01-02
NO20005462L (no) 2001-01-08
AU762792B2 (en) 2003-07-03
CA2331408C (en) 2008-10-21
ES2251218T3 (es) 2006-04-16
JP2002514595A (ja) 2002-05-21
WO1999058120A1 (en) 1999-11-18
DE69932645D1 (de) 2006-09-14
DK1075258T3 (da) 2003-12-01
EP1284139A1 (de) 2003-02-19
AU4936799A (en) 1999-11-29
DK1075260T3 (da) 2006-02-06
KR100822077B1 (ko) 2008-04-14
EP1285652B1 (de) 2006-08-16
US6365628B1 (en) 2002-04-02
ATE247464T1 (de) 2003-09-15

Similar Documents

Publication Publication Date Title
DE69910559D1 (de) Neue fettanaloge zur behandlung der fettleibigkeit
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
GR3031763T3 (en) Novel prostaglandin synthase inhibitors
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
TNSN01126A1 (fr) Imidazoles substitues nouveaux, procede pour leur preparation et compositions les contenant
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE60137243D1 (de) Fettsäure-analogen zur behandlung proliferierender hautstörungen
BR0212899A (pt) Compostos orgânicos
NO20014240D0 (no) C16-umettede FP-selektive prostaglandinanaloger
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
DE60204014D1 (de) Chlormethylierung von thiophene
MXPA03010821A (es) Composiciones de aroma y fragancias.
UA26982A1 (uk) Похідhі малоhової кислоти, які проявляють властивості іhгібітору росту рослиh
YU70799A (sh) Derivati tiazofurina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition